Meet AstraZeneca, Johnson & Johnson, Eli Lily and more at the 14th Annual RNA Therapeutics Conference 2023

On Nov 23, 2022

SAE Media Group reports: Network with the pharma and biotech global experts from UK and Europe at the RNA Therapeutics conference in London.

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%.

In 2023, we will see the return of SAE Media Group’s RNA Therapeutics conference to a live in-person event, showcasing an update on mRNA therapeutic applications, coupled with an industry outlook of the field.

The two-day agenda offers peer-to-peer networking with Directors of novel RNA therapies, CEOs, Senior and expert scientists, Chief Medical Officers, Senior Vice Presidents and many more.

Visit the website at: http://www.therapeutics-rna.com/PR2PharmaJournalist to download the brochure and view the full conference agenda
Don’t forget to register soon and take advantage of the Early Bird Offer available, to SAVE £200 until 30 November 2022!

Featured Key Conference Speakers Include:

Venkatesh Pilla Reddy, Director, Clinical Pharmacology and Pharmacometrics, AstraZeneca
Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, The Janssen Pharmaceutical Companies of Johnson & Johnson
Joseph Martinelli, Senior Director Genetic Medicine, Eli Lilly
Ying Yu, Associated Director, AbbVie
Martin Akerman, Chief Technical Officer, Envisagenics
Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca
Souphalone Luangsay, Senior Principal Scientist, Roche

Meet some of the leading expert speakers of the industry. A great meeting point for delegates to enhance their knowledge with the latest innovations in RNA application and RNA delivery techniques.

Some of the Key Sessions Include:

Developing Oligonucleotides into Therapies: Opportunities and Challenges

Introduction to oligonucleotide therapeutics and the current landscape
Therapeutic promise of oligonucleotide modalities
Outlining some of the key challenges in oligonucleotide therapeutics including extra-hepatic delivery
Exploring some of the emerging delivery solutions and future opportunities

Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca

Tailoring delivery systems for next generation mRNA therapeutics

Nanoparticle technologies for nucleotide and drug delivery systems
Structural and functional coherencies within selected delivery systems
Novel approaches and tailored solutions for future mRNA therapeutics

Heinrich Haas, Vice President, RNA Formulation & Drug Delivery, BioNTech

View the full agenda and speaker line-up at:

http://www.therapeutics-rna.com/PR2PharmaJournalist

Proudly sponsored by: eTheRNA, Polypeptide, Roche Diagnostics, Sartorius BIA Separations

For sponsorship enquiries contact Andrew Gibbons at

andrew.gibbons@saemediagroup.com or +44 (0) 20 7827 6156

For media enquiries contact Marketing, Lamprini Balasi at

lamprini.balasi@saemediagroup.com or +44 (0) 20 7827 6732

14th Annual RNA Therapeutics

8 – 9 February 2023

London, UK

#RNATx2023

Register by 30 Nov 2022 and SAVE £200!

http://www.therapeutics-rna.com/PR2PharmaJournalist

About SAE Media Group Conferences:

SAE Media Group Conferences connects global communities with focused networking conferences. We provide our customers with solutions through industry knowledge and collaboration that enables our attendees to return to their organisations better equipped to overcome their key business challenges. Our key events focus on Defence and Aerospace, Pharmaceutical and Medical. Each year we bring together over 5,000 senior business professionals at our conferences. http://www.smgconferences.com

SAE Media Group (SMG), a subsidiary of SAE International, reports the latest technology breakthroughs and design innovations to a global audience of nearly 1,000,000 engineers, researchers, and business managers. SMG provides critical information these professionals need to develop new and improved products and services.